Thanks for this piece. This is particularly so because I hope to setup a biotech phage based company that will produce phage based solutions like phage thereby and phage vaccines. From my experience, when propeople talk about startups in LMICs the emphasis is usually on tech startups. The environment favors tech startups and not biotech startups.
I will give you my experience, we won an Emergent venture grant to setup a phage bank. This we have done and at the same time we have been working on two projects: Developing phage therapy for local strains of Psuedomonas and Salmonella typhi. We are pushing for enabling policies as well as how to move on to the next stage.
It will be interesting to read more about how to move to the next stage if you have a biotech startup experience.
So far, we have phages that kill 80% of our local strains. Planning to get on to pre-clinical trials. But thats the problem, which funder will agree to invest thousands of Dollars in an African biotech startup. If you have some thoughts on these issues I will be glad to read more or to interact.
Thanks for this piece. This is particularly so because I hope to setup a biotech phage based company that will produce phage based solutions like phage thereby and phage vaccines. From my experience, when propeople talk about startups in LMICs the emphasis is usually on tech startups. The environment favors tech startups and not biotech startups.
I will give you my experience, we won an Emergent venture grant to setup a phage bank. This we have done and at the same time we have been working on two projects: Developing phage therapy for local strains of Psuedomonas and Salmonella typhi. We are pushing for enabling policies as well as how to move on to the next stage.
It will be interesting to read more about how to move to the next stage if you have a biotech startup experience.
So far, we have phages that kill 80% of our local strains. Planning to get on to pre-clinical trials. But thats the problem, which funder will agree to invest thousands of Dollars in an African biotech startup. If you have some thoughts on these issues I will be glad to read more or to interact.